Glucose Homeostasis in Pseudohypoparathyroidism

Stopped early

Conditions studied: Pseudohypoparathyroidism and Pseudopseudohypoparathyroidism, Pseudohypoparathyroidism Type Ia, Albright Hereditary Osteodystrophy

In brief

It is increasingly recognized that Pseudohypoparathyroidism type 1A (PHP1A) is associated with an increased risk of type 2 diabetes but the mechanism is unknown. In this pilot study we will assess β-cell function in patients with PHP1A and pseudopseudohypoparathyroidism PPHP.

Key facts

Study ID

NCT03761290

Run by

Vanderbilt University Medical Center

People needed

14

Starts

2019-06-19

Expected to finish

2021-04-30

Last updated by the study team

2026-05-04

Who can join

Age: 6 and older, up to 50. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of PHP1A/PPHP
• Age between 6 and 50 years old
• Controls will be matched based on:
• Gender
• Race
• Age (±2 years if <25 years old or ±5 years if ≥25 years old)
• BMI (±2 kg/m2)
• Diabetes status

You may not qualify if…

• Treatment with appetite-altering drug or initiation of a new weight loss program in the past 3 months
• Type 1 diabetes
• Type 2 diabetes treated with insulin or GLP-1 receptor agonists or A1c >9%at their most recent clinic visit
• Pregnant or lactating women

Where it is running

• Vanderbilt University Medical Center — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.